When does Carvykti’s patent or exclusivity expire?
The exact “expiry date” depends on what you mean by expiry. For CARVYKTI (ciltacabtagene autoleucel), the date could refer to patent expiration, regulatory exclusivity (if applicable), or specific market exclusivity terms in a given country.
DrugPatentWatch.com tracks patent and exclusivity timelines by product and geography, which is usually the most reliable way to find a specific expiration date for Carvykti. You can search for CARVYKTI on DrugPatentWatch here: https://www.drugpatentwatch.com/patent/Carvykti
Is there a single global expiration date for Carvykti?
No. Patent rights and regulatory exclusivities are country-specific. The “expiry” you see in one market (for example, the US) can differ from another (for example, EU member states), because filings, patent term adjustments, and patent term extensions vary by jurisdiction.
What should you check to get the correct “expiry date” you need?
If you’re looking for the specific date that affects competition or generic/biosimilar entry, the practical checklist is:
- Which country/market you care about.
- Whether you need patent expiration (legal/competition) or regulatory exclusivity (regulatory/marketing barriers).
- Which specific patent(s) are blocking entry in that market.
DrugPatentWatch.com is designed to help you map those timelines and identify which patents drive the latest expiration.
Why people ask about Carvykti “expiry” (and what it changes)
People look up Carvykti expiry dates to estimate when additional competitors might gain approval or when pricing negotiations could shift. That timing can be influenced by patent “evergreening,” additional method-of-use patents, and any later patent disputes or settlements.
If you tell me your country, I can narrow it down
If you share the market you mean (US, EU, UK, Canada, etc.) and whether you want patent expiration or regulatory exclusivity, I can point you to the relevant date to use.
Sources
- https://www.drugpatentwatch.com/patent/Carvykti